# Hope on the Horizon: Tau Treatment Breakthroughs Newsy: Alzheimer’s News Weekly Published: 2026-05-18T13:30:00.299Z Source: https://newsyai.com/edition/883880ec-e96a-4517-9b44-b765125b540a Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- **Alzheimer’s Treatment Briefing: Tau-Targeting Progress and Stem Cell Hope** **Coverage period: May 12–18, 2026** Below are this week’s most meaningful, truly **new** developments, ranked by impact on treatment options. **1. Tau-clearing drug shows early brain and symptom benefits in Phase 2 trial** - **Overview** On May 14, Biogen released top-line results from its CELIA Phase 2 study of diranersen (BIIB080), an experimental treatment given by spinal injection that targets tau—the twisted protein that forms harmful tangles inside brain cells. The drug lowered tau levels in the brain and appeared to slow memory and thinking decline in people with early Alzheimer’s, even though it did not hit its main goal for overall symptom improvement. Biogen says it will keep developing the drug, with fuller details coming at the Alzheimer’s Association International Conference in July.[[1]](https://www.alz.org/news/2026/topline-results-celia-phase-2-clinical-trial-tau-therapy-diranersen) - **Why this matters** Think of Alzheimer’s as a tangled garden hose that blocks water flow; clearing the kinks (tau) alongside removing leaves (amyloid plaques) could keep the “brain garden” healthier longer. This is one of the first clear signs that a tau-focused approach can change both the biology and daily function—opening the door to combination treatments that attack the disease from two sides at once. **2. Stem cells added to existing drugs in new Miami trial** - **Overview** The University of Miami Miller School of Medicine launched a small investigator-led study testing a single IV infusion of mesenchymal stem cells (special repair cells from donors) on top of standard anti-amyloid medicines like Leqembi or Kisunla. The goal is to see if the stem cells can calm brain inflammation, support repair, and help stabilize thinking skills in people with mild cognitive impairment or early Alzheimer’s. Participants must be 55–90, already on plaque-clearing therapy for at least six months, and have a study partner. The trial builds on earlier safety data that showed no serious side effects and hints of cognitive stability.[[2]](https://news.med.miami.edu/stem-cell-therapy-alzheimers-clinical-trial-miami/) - **Why this matters** Current plaque-clearing shots are like using a vacuum on a dirty floor—they remove the mess but don’t fix the underlying wear and tear. Adding stem cells is like bringing in a repair crew that may reduce swelling and help brain cells recover. If successful, this “add-on” strategy could turn today’s approved treatments into stronger, longer-lasting options without starting from scratch. ## What this means for care right now - Ask your doctor about emerging tau trials if you or a loved one has early symptoms—more data arrives this summer. - Watch for combination studies that pair approved drugs with new approaches like stem cells; these may become available sooner than brand-new single therapies. - Early blood tests remain the best way to check eligibility for any new study or treatment. ## Sources - Tau therapy results: [Alzheimer’s Association](https://www.alz.org/news/2026/topline-results-celia-phase-2-clinical-trial-tau-therapy-diranersen)[[1]](https://www.alz.org/news/2026/topline-results-celia-phase-2-clinical-trial-tau-therapy-diranersen) - Stem cell trial: [University of Miami Miller School of Medicine](https://news.med.miami.edu/stem-cell-therapy-alzheimers-clinical-trial-miami/)[[2]](https://news.med.miami.edu/stem-cell-therapy-alzheimers-clinical-trial-miami/) Fresh approaches keep the pipeline moving—2026 continues to bring incremental but real steps forward.